GC Genome Corp., a South Korean diagnostics company, announced on Thursday that it recently signed seven service contracts for diagnostic testing with six companies across the Middle East and Asia. These agreements were a result of its negotiations at Med Lab, a global bio exhibition held in February 2024, where the biotech firm engaged with major molecular diagnostic firms and medical organizations regarding collaborations on genome analysis services for diagnostic purposes.

The contracts include partnerships with six buyers in the Middle East spanning Jordan, Saudi Arabia, and Oman, with an additional one in Pakistan.

The buyers were said to be interested in new products recently developed by GC Genome, including GreenPlan HRD, a specialized genetic test that enables precise diagnosis and treatment planning for patients with solid tumors.

A recent series of contracts will allow the company to partner with corporate entities authorized by prestigious accreditation bodies such as the Joint Commission International (JCI), the Saudi Center for Disease Prevention and Control (SCDC), and the Saudi Central Board for Accreditation of Healthcare Institutions (CBAHI).

GC Genome has actively promoted its screening services at Med Lab over the past three years, and its consistent participation has yielded favorable feedback from existing clients.

“The Middle East has a significant demand for genetic testing, alongside a burgeoning interest in genomic analysis services for screening and diagnosis due to constraints in the local medical workforce. Leveraging our foothold in the region, we aim to explore expansion opportunities into European markets,” GC Genome Chief Executive Ki Chang Seok said.

By Kim Jee-hee and Han Yubin

[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]